Baseline characteristics in patients with interstitial lung diseases as predictors for progression: a real life study
References
- W. D. Travis et al., “An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic inter-stitial pneumonias,” Am J Respir Crit Care Med, vol. 188, no. 6, pp. 733–748, Sep. 2013, doi: 10.1164/rccm.201308-1483ST.
- B. Kaul, V. Cottin, H. R. Collard, and C. Valenzuela, “Variability in Global Prevalence of Interstitial Lung Disease,” Frontiers in Medicine, vol. 8. Frontiers Media S.A., Nov. 04, 2021. doi: 10.3389/fmed.2021.751181.
- G. Raghu et al., “Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,” Am J Respir Crit Care Med, vol. 205, no. 9, pp. E18–E47, May 2022, doi: 10.1164/rccm.202202-0399ST.
- M. Wijsenbeek and V. Cottin, “Spectrum of Fibrotic Lung Diseases,” New England Journal of Medicine, vol. 383, no. 10, pp. 958–968, Sep. 2020, doi: 10.1056/nejmra2005230.
- M. Kolb and M. Vašáková, “The natural history of progressive fibrosing interstitial lung diseases,” Respiratory Research, vol. 20, no. 1. BioMed Central Ltd., Mar. 14, 2019. doi: 10.1186/s12931-019-1022-1.
- L. Richeldi et al., “Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis,” New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, May 2014, doi: 10.1056/nejmoa1402584.
- Monitorul Oficial al Romaniei – Anul 190 (XXXIV) – Nr 242 Bis, 2022, pp. 69–72.
- Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA. MUC5B and Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S193-9. doi: 10.1513/AnnalsATS.201503-110AW. PMID: 26595739; PMCID: PMC4722833.
- C. J. Ryerson et al., “Predicting survival across chronic interstitial lung disease: The ILD-GAP model,” Chest, vol. 145, no. 4, pp. 723–728, 2014, doi: 10.1378/chest.13-1474.
- A. W. Wong, C. J. Ryerson, and S. A. Guler, “Progression of fibrosing interstitial lung disease,” Respiratory Research, vol. 21, no. 1. BioMed Central Ltd., Jan. 29, 2020. doi: 10.1186/s12931-020-1296-3.
- S. L. F. Walsh et al., “Role of imaging in progressive-fibrosing interstitial lung diseases,” European Respiratory Review, vol. 27, no. 150. European Respiratory Society, 2018. doi: 10.1183/16000617.0073-2018.
- Irina Strambu, Ionela Belaconi, and Voicu Tudorache, “TOMOGRAFIA COMPUTERIZATÃ CU ÎNALTÃ REZOLUTIE (HRCT),” in GHID DE DIAGNOSTIC SI TRATAMENT AL PNEUMOPATIILOR INTERSTITIALE DIFUZE, 2015.
- J. H. Fisher et al., “Baseline characteristics and comorbidities in the CAnadian Registry for Pulmonary Fibrosis,” BMC Pulm Med, vol. 19, no. 1, Nov. 2019, doi: 10.1186/s12890-019-0986-4.
- Kawano-Dourado L, Doyle TJ, Bonfiglioli K, et al. Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis. Chest 2020, 158(4), pp. 1546–1554, doi.org/10.1016/j.chest.2020.04.061
- Langford B, Diamantopoulos A, Maher TM et al. Using data on survival with idiopathic pulmonary fibrosis to estimate survival with other types of progressive fibrosis interstitial lung disease: a Bayesian framework. Adv Therap 2021. 39(151). DOI: 10.1007/s12325-021-02014-z.
- van de Sar I, Jones S, Clarke DL, Bonella F, Fourrier JM, Lewandowska K, Bermudo G, Simidchiev A, Strambu IR, Wijsenbeek MS, Parfrey H. Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: a multinational European survey. Front Med 2021. 8:711194. DOI: 10.3389/fmed.2021.711194
Language: English
Page range: 64 - 70
Published on: Jun 10, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Keywords:
Related subjects:
© 2024 Ștefan Teodorescu-Drăghicescu, Irina Strâmbu, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.